NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.…
NewcelX Announces Pricing of $1.55 Million Equity Financing at 20% Premium Pricing to Market
NewcelX (NASDAQ: NCEL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 9 employees.
The shares were at 2.540 USD on 20 November 2026, down 31.0% over 52 weeks. Its 52-week range is 1.830 USD to 5.120 USD: the price is 50.4% below the high and 38.8% above the low.
At a market capitalisation of 14.67M USD, it trades at 4.9 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 85% for NCEL.
NewcelX reports return on equity of -114.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 318.00K USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.
No upcoming events tracked.